Thanks Madam for comprehensive statistics.
It will be interesting to see how the market responds if MSB go to market in Japan. In my opinion this alone will in the eyes of investors validate the product (I also think it will be the first stem cell therapy to go to market).
More than likely impossible to compare but market reaction does interest me. Eg below
The Sirtex information as supplied by Kakala (I think)seen its share price "share price in Sirtex Medical soared 136 per cent in 2014, ".........Sirtex's 2013-14 revenue was $131 milliion"
........."
The therapy is considered by most oncologists to be a 'second-line' defence, but Sirtex is hoping to promote its therapy as a first-line defence on the back of a long running trial that is due to report in March.
Do you think the markets mentioned in below will signifantly boost revenue for the MSC-100-1 on top of Japan revenue?
"Mesoblast expects to have paediatric data 2016 & will launch product in Canada & NZ on the back of this, as conditional marketing approval has already been granted".
http://www.fnarena.com/index2.cfm?type=dsp_newsitem&n=563C6F4B-BD23-2924-260B930216DC815
Apologists, page-42
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.005(0.32%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.52 | $6.446M | 4.092M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 62215 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 14678 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |